Clinical Trials Browser

Phase 1/2 × OTHER × Diabetes Mellitus, Insulin-Dependent, 12 × Clear all

Turcot syndrome, Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04631731 2023-06-01

ICEMELT

Phase 1/2 Unknown

200 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Stomach Neoplasms, Endometrial Neoplasms

NCT03354962 2020-12-04

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Phase 1/2 Terminated

6 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT03356782 2020-06-11

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Phase 1/2 Unknown

20 enrolled

Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Bone Neoplasms, Sarcoma, Sarcoma, Ewing

NCT03182803 2017-06-09

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

NCT03182816 2017-06-09

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

NCT03179007 2017-06-07

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

Clinical Trials

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

ICEMELT

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor